Welcome to BioSeeker Group!

Triple Analysis: Melanoma, Pancreatic Cancer and Antibodies

Additional Information

Published Date Jun 12, 2013
Special Offer

You can deduct the full value of this report within 30 days of purchase towards a Cancer Highlights subscription.
Read more about becoming a Cancer Highlights subscriber here.

Pages 4645
PDF Fact Sheet View Fact Sheet for the report Triple Analysis: Melanoma, Pancreatic Cancer and Antibodies in PDF
Format PDF
Publisher BioSeeker Group
Product Line

Find the Triple Analysis Report in oncology which best suits your needs by selecting any three (3) out of these 14 high impact Cancer Focus Areas.

Availability: In stock

$3,450.00

Quick Overview

This triple analysis focuses on cancer drug development strategies in both Melanoma and Pancreatic Cancer and by the compound strategy of Antibodies.

Request Sample Pages or Access via 1stOncology™

  • You can request Free Sample Pages to Triple Analysis: Melanoma, Pancreatic Cancer and Antibodies.

    To find out more about Triple Analysis: Melanoma, Pancreatic Cancer and Antibodies, please read the product description below.
    We also are happy to email you out free sample pages which contain screen shots and more information on the methodology behind the product.

    Did you know that Triple Analysis: Melanoma, Pancreatic Cancer and Antibodies is part of the 1stOncology™ platform and can be accessed at no extra cost?

    1stOncology™ allows you to always stay on top of what is really going on in the world of cancer drug development and have an edge when it comes to Search & Evaluation, Indication Selection & Expansion, Target Scouting, First-in-Class analysis and much, much more.


    Or

This triple analysis focuses on cancer drug development strategies in both Melanoma and Pancreatic Cancer and by the compound strategy of Antibodies. Each of these three individual parts is evaluated according to standardized criteria in a five pillar pipeline drug assessment methodology to compare drug development strategies in oncology. This makes it easy to find and compare analysis not only within one single cancer focus area but also between different areas.

Below is a short synopsis of each part included in this report:

Part I: Melanoma
The melanoma drug report part comprises defined and up to date development strategies for 282 drugs within the portfolio of 164 companies world-wide, from Ceased to Marketed. The report extensively analyses their 226 identified drug targets, organized into 187 drug target strategies, and assesses them in melanoma.
This part is based on the following publication:
Melanoma Drug Development Analysis: From First-in-Class to Best-in-Class?

Part II: Pancreatic Cancer
The pancreatic cancer report part comprises defined and up to date development strategies for 247 pancreatic cancer drugs within the portfolio of 158 investigators, from Ceased to Marketed. This part extensively analyses their 197 identified drug targets, organized into 163 drug target strategies, and assesses them in eight different compound strategies.
This part is based on the following publication:
Commercializing Pancreatic Cancer Drugs: The Faster Route to Consider Your Options and Position of Others

Part III: Antibodies
The antibody drug report part comprises defined and up to date development strategies for 572 drugs in oncology within the portfolio of 205 companies world-wide, from Ceased to Marketed. The report extensively analyses their 270 identified drug targets, organized into 279 drug target strategies, and assesses them in 72 cancer indications.
This part is based on the following publication:
Cancer Antibodies: Drug Target Atlas and Competitive Outlook

The report is written for you to understand and assess the impact of competitor entry and corresponding changes to development strategies for your own portfolio products. It helps teams to maximize molecule value by selecting optimal development plans and manage risk and uncertainty. The report serves as an external commercial advocate for pharmaceutical companies’ pipeline and portfolio planning (PPP) in cancer by:

* Providing you with competitive input to the R&D organization to guide development of early product ideas and ensure efforts are aligned with business objectives

* Assisting you to make informed decisions in selecting cancer indications that are known to be appropriate for your drug’s properties

* Analyzing, correlating and integrating valuable data sources in order to provide accurate data for valuation of pipeline, in-licensing and new business opportunities

* Providing you with commercial analytic support for due diligence on in-licensing and acquisition opportunities

* Supporting development of integrative molecule, pathway and disease area strategies

* Integrating knowledge for you to consider the therapeutic target for the highest therapeutic outcome and return on investment

This report provides systems, analytical and strategic support both internally to PPP and to stakeholders across your own organization. The report will also be an important part of creating and implementing a market development plan for cancer drugs to insure that the optimal market conditions exist by the time the products are commercialized.

Key Topics Covered:

Part I: Melanoma
5.1 The Scope of this Report 26
6 Consider the Therapeutic Target Among Melanoma Drugs for the Highest Therapeutic Outcome and Return on Investment (226 Drug Targets) 30-467
7 First-in-Class and Me-too Analysis of Melanoma Drugs (187 Drug Target Strategies and 282 Drugs) 468-677
8 Is First-in-Class the Best-in-Class? 488-678
9 Compound Strategies at Work: Competitive Benchmarking of Melanoma Drugs by Compound Strategy (7 Compound Strategies) 679-710
10 The Competition Through Close Mechanistic Approximation of Melanoma Drugs 711
11 Pipeline and Portfolio Planning: Competitive Benchmarking of the Melanoma Drug Pipeline by Company (164 Companies and 282 Drugs) 716-1165
12 Disclaimer 1166
Figures: Includes 5 Figures
Tables: Includes 222 Tables
Total Number of Pages: 1,181

Part II: Pancreatic Cancer
5.1 The Scope of this Report 27
6 Consider the Therapeutic Target Among Pancreatic Cancer Drugs for the Highest Therapeutic Outcome and Return on Investment (197 Drug Targets) 31-422
7 Emerging New Products to Established Ones: Drug Target Strategies of Pancreatic Cancer Drugs by their Highest Stage of Development (163 Drug Target Strategies and 247 Drugs) 423-612
8 Compound Strategies at Work: Competitive Benchmarking of Pancreatic Cancer Drugs by Compound Strategy (8 Compound Strategies) 613-651
9 Pipeline and Portfolio Planning: Competitive Benchmarking of the Pancreatic Cancer Drug Pipeline by Investigator (158 Investigators and 247 Drugs) 652-1088
10 Drug Index 1091
11 Company Index 1098
Figures: Includes 7 Figures
Tables: Includes 218 Tables
Total Number of Pages: 1,103

Part III: Antibodies
5.1 The Scope of this Report 35
6 Consider the Therapeutic Target Among Antibody Drugs in Cancer for the Highest Therapeutic Outcome and Return on Investment (270 Drug Targets) 39
7 Emerging Drug Candidates to Established Ones: Drug Target Strategies of Antibody Drugs in Cancer by their Highest Stage of Development (279 Drug Target Strategies and 572 Drugs) 423-776
8 Selecting Indication for Antibody Drugs in Oncology (72 Cancer Indications) 777-907
9 Pipeline and Portfolio Planning: Competitive Benchmarking of the Cancer Antibody Drug Pipeline by Investigator (205 Investigators and 572 Drugs) 908-2360
10 Disclaimer 2361
Figures: Includes 7 Figures
Tables: Includes 355 Tables
Total Number of Pages: 2,361

This Report Includes the Following Companies:
3SBio
A&G Pharmaceutical
AB Science
Abbott
AbbVie
Abcam
Abiogen
Ablynx
AC Immune
Acceleron Pharma
Access
Actelion
Actinium Pharmaceuticals
Active Biotech
Adherex
Advanced Life Sciences
Advantagene
Advaxis
AEgera
Affibody
Affimed Therapeutics
Affitech
Agenus
AGY Therapeutics
Aida Pharmaceuticals
Alder Biopharmaceuticals
Alethia Biotherapeutics
Alexion
Algeta
Alnylam
AlphaVax
ALSP
Altor BioScience
Ambit Biosciences
Amgen
Amorfix Life Sciences
AngioChem
Antisense Pharma
Antisoma
Anza Therapeutics
Aphios
Apogee Biotechnology
ApopLogic Pharmaceuticals
Apotex
Apricus Biosciences
Arana Therapeutics
Arca biopharma
Ardea Biosciences
Areva
arGEN-X
Ariad
ArQule
Array BioPharma
Astellas
Astex Pharmaceuticals
AstraZeneca
Attenuon
AVEO
AVI BioPharma
Bayer
Berkeley Lab
Betapharma
Bio-Medisinsk Innovasjon
BioAlliance Pharma
Biocon
Biogen Idec
BioInvent
Biokine Therapeutics
Biolex
BioLineRx
Bionovo
BioNTech
BioNumerik
BioSante
Biosceptre
Biotech Ltd
Biotecnol
Biotest
BioVex
Boehringer Ingelheim
Bristol-Myers Squibb
BTG
Calando Pharmaceuticals
Cancer Advances
Cancer Innovations
Cancer Research Technology
CDG Therapeutics
Celera
Celgene
Cell Therapeutics
Celldex Therapeutics
Celltrion
Celsion
Celtic Pharma
Center of Molecular Immunology
Centrose
CG Therapeutics
Circadian Technologies
CJ Corp
Clavis Pharma
CompleGen
Cornerstone Pharmaceuticals
Cosmo Pharmaceuticals
CritiTech
CSL
CuraGen
Curaxis
CureTech
Curis
Customized Therapeutics
Cyclacel
Cylene Pharmaceuticals
Cynvec
CytImmune Sciences
Cytokinetics
CytRx
Daewoong
Daiichi Sankyo
Dara Biosciences
Deciphera Pharmaceuticals
Dendreon
DiaMedica
DNAVEC
Dompe
Dong-A
Dr Reddy’s
Dyax
EGEN Inc
Eisai
Elan
Eli Lilly
Emergent BioSolutions
EntreMed
Enzon
Epeius Biotechnologies
EpiCept
Ergon Pharmaceuticals
Esperance Pharmaceuticals
EUSA Pharma
Exelixis
Expression Drug Designs
Fabrus
Faron Pharmaceuticals
Favrille
Femta Pharmaceuticals
FibroGen
Five Prime Therapeutics
Flamel Technologies
Fusion Antibodies
Galaxy Biotech
Galectin Therapeutics
GammaCan
Ganymed Pharmaceuticals
Gene Techno Science
Genencor
Genentech
Genmab
Genomic Systems
GenPat77
Genta
GenVec
Geron
Gilead Sciences
GlaxoSmithKline
Gliknik
GlycoGenesys
Glycotope
Gradalis
Green Cross
Hawthorn Pharmaceuticals
Hemispherx Biopharma
Hoffmann-La Roche
Human Genome Sciences
Ichor Medical Systems
Idera Pharmaceuticals
IDM Pharma
ImClone Systems
IMED
Immune Pharmaceuticals
ImmunoCellular Therapeutics
Immunocore
ImmunoGen
Immunomedics
Immunovaccine
ImmuPharma
Immutep
Incyte Corporation
Infinity Pharmaceuticals
Innate Pharma
InNexus Biotechnology
Innovive
Inotek
Inovio
Insmed
Insys Therapeutics
Intas Biopharmaceuticals
Intracel
Intrexon
Introgen Therapeutics
Ipsen
ISA Pharmaceuticals
ISU ABXIS
Jennerex Biotherapeutics
Johnson & Johnson
Kadmon
KAEL-GemVax
Kaketsuken
KaloBios
Kalypsys
Karyon-CTT
Kiadis
Kirin Pharma
Kissei
Kyowa Hakko Kirin
Kyto Biopharma
Leo
LFB Biotechnologies
LG Life Sciences
Ligand
Lipotek
MacroGenics
Mannkind
MAT Biopharma
MBiotec
Meda
Medarex
MediGene
MedImmune
Medisyn Technologies
Menarini
Merck & Co
Merck KGaA
Merrimack
Mersana Therapeutics
MethylGene
Micromet
Mitsubishi Tanabe Pharma
Mochida
Mojave Therapeutics
MolMed
Mologen
Mycenax
Nektar Therapeutics
Neovacs
Nereus Pharmaceuticals
Neuren
NIH
Nippon Kayaku
Nippon Shinyaku
NKT Therapeutics
Non-industrial source
Northwest Biotherapeutics
Novacea
NovaLead
Novartis
Novogen
Oasmia
Oncalis
OncoMed
OncoTherapy Science
Oncothyreon
Oncovir
Oncozyme Pharma
Onyvax
Oxford BioMedica
OXiGENE
Pacific Biotech
Paladin Labs
Panacea
PanaGin
PanGenetics
Patrys
PBL Therapeutics
Pepscan Therapeutics
Peregrine Pharmaceuticals
Perseus Proteomics
Pfizer
PharmAbcine
Pharmacyclics
PharmaMar
Pharmexa
Philogen
PhiloGene
Pierre Fabre
Piramal
Prima Biomed
PROBIOMED
ProCell Therapeutics
Prochon Biotech
Progen
Progenics Pharmaceuticals
ProMetic Life Sciences
Protgen
Ramot
Ras Therapeutics
Reata Pharmaceuticals
Recepta biopharma
Receptor BioLogix
Regeneron
Regulon
Reliance Life Sciences
RESprotect
Rexahn
Rigel
Rottapharm Madaus
Samyang
Sanofi
Santaris Pharma
Santhera Pharmaceuticals
Sareum
SBI Biotech
Scancell
Seattle Genetics
Shanghai CP Guojian
Shenogen
Shire
Simcere Pharmaceuticals
Solbec Pharmaceuticals
Spirogen
Stainwei Biotech
Sunesis
Sunol Molecular
SuperGen
SuppreMol
Swedish Orphan Biovitrum
Switch Pharma
Symphogen
Synageva BioPharma
SynerGene Therapeutics
Synta Pharmaceuticals
Tactic Pharma
Taiho
Takeda
Talon Therapeutics
Tamir Biotechnology
Tapestry Pharmaceuticals
Targa Therapeutics
Targepeutics
Tau Therapeutics
TeGenero
Teva
Thallion Pharmaceuticals
Therion Biologics
ThromboGenics
Titan Pharmaceuticals
to-BBB
Tolerx
TopoTarget
Tracon Pharmaceuticals
Tragara Pharmaceuticals
Transgene
Trillium Therapeutics
Trion Pharma
UCB
UMN Pharma
United Therapeutics
Vaccinex
Wakunaga
VasGene Therapeutics
VaxOnco
VBL Therapeutics
Vectura
Vertex Pharmaceuticals
Vical
Wilex
Vion Pharmaceuticals
VioQuest
Viragen
ViroMed
Viventia Biotech
WntResearch
XBiotech
Xencor
Xerion
Xoma
Y’s Therapeutics
Yakult Honsha
YM BioSciences
York Pharma
Zenotech
Zeria
A Shortlist of Drugs Included are:
131I-tositumomab
abagovomab
adecatumumab
AEB071
AEG-35156
aflibercept
agatolimod
AGS-1C4D4
ALD-518
aldesleukin
alemtuzumab
ALT-801
amatuximab
AME-133
AMG-386
APO-866
apricoxib
ARC-100
ARQ-197
ARRY-438162
astuprotimut-r
Auto TAG vaccine
AV-299
axitinib
bardoxolone methyl
belimumab
belinostat
bevacizumab
BHQ880
blinatumomab
BMS-663513
BMS-936558
bortezomib
bosutinib
brentuximab vedotin
brivanib alaninate
brivudine
BT-062
Buparlisib
Cabozantinib
capecitabine
carlumab
catumaxomab
CB-10-01
CDX-1307
CDX-1401
celecoxib
cetuximab
CG-201
cilengitide
cixutumumab
CMAB302
CMAB304
conatumumab
cositecan
CPI-613
CRLX-101
CT-011
dalotuzumab
daratumumab
dasatinib
decitabine
denenicokin
denileukin diftitox
denosumab
dinaciclib
docetaxel
dovitinib lactate
doxorubicin
E-7820
E7449
elotuzumab
EMD-273063
EMD525797
endostatin
eniluracil
entinostat
enzastaurin hydrochloride
epirubicin
epratuzumab
epratuzumab-Y90
erlotinib
ertumaxomab
everolimus
Exherin
farletuzumab
figitumumab
fresolimumab
galiximab
ganetespib
ganitumab
gefitinib
gemtuzumab ozogamicin
girentuximab
glembatumumab vedotin
golvatinib
GS-6634
GSK-1120212
GSK-2118436
GV-1001
GVAX
Hi-8 MEL
histamine dihydrochloride
I-131-labetuzumab
ibritumomab tiuxetan
icotinib hydrochloride
icrucumab
imatinib mesilate
IMP-321
INCB-24360
inotuzumab ozogamicin
interferon
interleukin-12
interleukin-2
intetumumab
IPH-1101
IPH-2102
ipilimumab
iratumumab
irinotecan
irinotecan hydrochloride
ispinesib mesylate
JX-594
kahalalide F
KD032
L19-IL2
L19-TNFalpha
Lambrolizumab
lapatinib ditosylate
LEE-011
lenvatinib
lestaurtinib
LGX818
lintuzumab
LIP-131I
LipoVIL12
lorvotuzumab mertansine
lucatumumab
lumiliximab
LY2495655
lymphomun
MABp1
mapatumumab
masitinib
MCS-110
MDX-1379
MEDI-551
MEDI-573
MetXia
MGN-1601
milatuzumab
milatuzumab-doxorubicin
MKC-1
MKC-1106-MT
MM-111
MM-121
mocetinostat
mogamulizumab
MOR202
MOR208
MORAb-004
motexafin gadolinium
moxetumomab pasudotox
nadroparin
naptumomab estafenatox
natalizumab
necitumumab
nilotinib
nimotuzumab
obinutuzumab
oblimersen sodium
ofatumumab
olaparib
olaratumab
onartuzumab
OncoVAX
Onyvax-105
oregovomab
OTS-102
P-276-00
P276-00
paclitaxel
PancAtak
panitumumab
panobinostat
pasireotide
pasireotide LAR
PAT-SC1
pazopanib hydrochloride
PCI-27483
peginterferon alfa-2b
pemetrexed disodium
pentamidine isethionate
perifosine
pertuzumab
PF-4856884
pimasertib
plitidepsin
poly-ICLC
PX-12
RAF-265
ramucirumab
Reditux
retaspimycin
Rexin-G
RG-7160
rhIFN-alpha
ridaforolimus
rilotumumab
rintatolimod
rituximab
robatumumab
romidepsin
romiplostim
RX-0201
sagopilone
samalizumab
SAR-3419
sargramostim
SCIB-1
selumetinib
siltuximab
sorafenib tosylate
sotatercept
ß-lapachone
sunitinib malate
Sym-004
talminogene laherparepvec
tegafur + uracil
temsirolimus
Tenarad
tesetaxel
thalidomide
thymalfasin
tigatuzumab
tocilizumab
trabedersen
trastuzumab
TRC-105
tremelimumab
triciribine phosphate
TRU-016
TS-1
tucotuzumab celmoleukin
U3-1287
Ublituximab
varlitinib
velimogene aliplasmid
veliparib
veltuzumab
vemurafenib
verubulin
vinflunine ditartrate
vismodegib
vitespen
volociximab
WX-671
YM-155
yttrium Y 90 clivatuzumab tetraxetan
Z-360
zalutumumab
zanolimumab

Request Sample Pages or Access via 1stOncology™

  • You can request Free Sample Pages to Triple Analysis: Melanoma, Pancreatic Cancer and Antibodies.
    To find out more about Triple Analysis: Melanoma, Pancreatic Cancer and Antibodies, please read the product description below.
    We also are happy to email you out free sample pages which contain screen shots and more information on the methodology behind the product.

    Did you know that Triple Analysis: Melanoma, Pancreatic Cancer and Antibodies is part of the 1stOncology™ platform and can be accessed at no extra cost?

    1stOncology™ allows you to always stay on top of what is really going on in the world of cancer drug development and have an edge when it comes to Search & Evaluation, Indication Selection & Expansion, Target Scouting, First-in-Class analysis and much, much more.


    Or

Other selected research from the 'Triple Analysis' category:


Triple Analysis: Colorectal Cancer, Leukemia and Protein Kinase Inhibitors
This triple analysis focuses on cancer drug development strategies in both Colorectal Cancer and Leukemia and by the mechanism/target/effect of Protein Kinase Inhibitors. Learn More


Triple Analysis: Lung Cancer, Protein Kinase Inhibitors and Antibodies
This triple analysis focuses on cancer drug development strategies in one specific cancer indication (Lung Cancer), one mechanism/target/effect area (Protein Kinase Inhibitors) and one compound specific area (Antibodies). Learn More

Other selected research from the 'Oncology' category:


Competitive Handbook towards Personalized Medicine in Prostate Cancer
This report is a new and unique way of stratifying and analyzing the global prostate cancer pipeline towards personalized medicine and presents actionable analysis Learn More


Triple Analysis: Prostate Cancer, Apoptosis and Antibodies
This triple analysis focuses on cancer drug development strategies in one specific cancer indication (Prostate Cancer), one mechanism/target/effect area (Apoptosis) and one compound specific area (Antibodies). Learn More